Frequency of Red Cell Alloimmunization in Patients with Thalassemia Major: A Report from the Southwest of Iran

Bijan Keikhaei¹, Homayoun Yousefi¹, Arash Alghasi¹, Asaad Sharhani², Roya Khazaei^{1*}

1. Thalassemia & Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

2. Department of Epidemiology and Biostatistics, school of Health, Social determinants of health research center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran,

*Corresponding author: Dr. Roya Khazaei, Thalassemia & Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Email: karami.9926@gmail.com. ORCID ID: 0009-0006-5262-8694

Received: 15 July 2023 Accepted: 12 Spetember 2023

Abstract

Background: The mainstay of managing severe β -thalassemia remains lifelong blood transfusion. Mismatched red blood cell phenotypes between donors and recipients in multiple blood transfusions can result in the development of alloimmunization in recipients. The aim of this study was to determine the frequency of major and subgroup antigens and their phenotypes in thalassemia major patients.

Materials and Methods: This cross-sectional descriptive study was performed on 105 patients with thalassemia major who referred to Baghaei Hospital in Ahvaz in 2021. Their alloimmunization to erythrocyte antigens was determined with standard tubular antibody search kits.

Results: Among the thalassemia major patients participating in the study, 51 were female (48.45%). The mean age of the participants was 21.10 ± 5.8 years. Out of the 105 patients studied, 26 had detectable alloantibodies in the serum (24.7%). The two groups of patients with positive and negative alloantibodies were significantly different in terms of Rh and C blood groups (P-values of 0.03 and 0.05, respectively). There was no significant association between the existence alloantibody and age, gender, spleen condition and the time of first transfusion (P > 0.05).

Conclusion: It was concluded that red blood cell matching, at least for Rh and C groups, is necessary to prevent alloimmunization in thalassemia major patients.

Keywords: Alloimmunization, Major thalassemia, Transfusion

Introduction

Thalassemia is one of the most common congenital hemolytic disorders characterized by the decreased synthesis of one or more hemoglobin polypeptide chains (1-3). A constant characteristic of β-thalassemia major patients is severe anemia caused by ineffective erythropoiesis and hemolysis, both of which are due to the partial or complete suppression of β -globin chain synthesis (2, 4). The only way of survival in β thalassemia major is regular blood transfusion (5). The purpose of treatment sustain the pre-transfusion to is hemoglobin level above 9.5 g/dl (6). Blood transfusion, despite being a life-saving process, is associated with inherent risks of alloimmunization against red cells antigens

(7). Alloimmunization is a major concern in the treatment of thalassemia as it can be life-threatening (8). Since only ABO and RH groups are controlled when a blood type is selected for transfusion, most alloantibodies are developed against other blood groups and cause delayed hemolytic reactions, which are considered as crossmatching (9, 10). Early diagnosis and identification of alloantibodies are very critical because blood transfusion is crucial for patients' survival (10, 11). Antibody screening and recognition can help to detect antigens (11). It is to be noted that, in developed countries, antibody screening is included in the compatibility testing protocol, but it is not carried out for all thalassemia patients in Iran (12). Previous

studies have shown that the rate of alloimmunization in thalassemia patients varies from 2.5% to 37% in different regions of the world (13). The risk of alloantibody development still remains a major challenge, especially in developing countries where the high costs of pretransfusion phenotyping do not allow it to be part of the routine blood transfusion practice (14). In Iran, pre-transfusion testing includes ABO grouping and Rh (D) typing, and groups other than ABO and Rh "D" (such as Kell, Duffy, Kidd, MNS, and Lewis) are not routinely dealt with (15). So, the extent of erythrocyte antigen profiling among the donor population, especially groups other than ABO and Rh "D", is not clear. This is because there are very limited data in the literature for these subgroups, and statistical differences have been found among different racial groups (13). Considering the annual birth of more than 600,000 babies with thalassemia worldwide who need treatment and regular blood transfusions, it seems necessary to investigate the involved factors in different ethnicities and provinces of Iran (16). Due to the high number of the patients with thalassemia major in Khuzestan Province, southwest of Iran, and the importance of alloimmunization as a factor for treatment failure, the current study aimed to determine the frequency of major and subgroup antigens and their phenotypes in thalassemia major patients.

Materials and Methods

This cross-sectional and descriptive study was conducted on 105 Iranian βthalassemia major patients referring to Baghaei Hospital in Ahvaz and receiving blood in 2021. There were 51 (48.45%) females with the mean age of 21.10 ± 5.8 years. The inclusion criteria were dependence on transfusion and a history of blood transfusion at least once a month. The patients with sickle cell anemia, positive history of intravenous gammaglobulin, and thalassemia intermedia were excluded from the study. The clinical and transfusion records of the enrolled patients were collected with a questionnaire on age, gender, blood groups, age at the first transfusion, the total number of transfused RBC units, and splenectomy status. After informed consent was received from the patients or their elderlies, blood samples were collected in ethylenediamine tetraacetic acid (EDTA) tubes on the purpose of ABO/RhD blood grouping. The antibody screening (through an indirect Coombs test) was carried out by the gel process. This test was conducted in compliance with the standard procedure. The samples were tested for ABO group and Rh (D) type, and an antibody screen test (using an IBTO home-made kit) was conducted through the standard tube procedure. To identify the alloantibodies, that standard tube procedure was implemented in three phases. Antibody performed screening was using а commercial 11-cell identification panel (Dia panel, Bio-Rad, Switzerland).

Finally, the rate of the identified alloantibodies was calculated, and the relationship between the occurrence of alloantibodies and the variables of age in the first blood transfusion, gender, frequency of blood injection, and spleen status was investigated.

Ethical Consideration

Written consent was obtained from the patients or their parents. This study was approved by the ethics committee of Jundishapur University of Medical Sciences, Ahvaz, Iran (IR.AJUMS.REC.1399.251).

Statistical analysis

The data analysis was performed using SPSS (version 22; SPSS Inc., Chicago, IL, USA). The quantitative and qualitative variables were reported with mean \pm SD and frequencies (percentages), respectively. Chi-square tests or Fisher's

261

Iran J Ped Hematol Oncol. 2023, Vol 13, No 4, 260-268

extract tests were used to examine the associations. Independent t-tests were also used for the quantitative comparisons of the two groups. A P-value less than 0.05 was considered statistically significant.

Results

Of the total number of 105 patients with thalassemia major, 51 (48.45%) were females with the mean age of 21.10 ± 5.8 years. The mean age in the first blood transfusion was 4.9 ± 1.3 years. As reported in Table I, the patients were divided into alloantibodies positive (n =26) and negative groups (n = 79). These two groups were not significantly different in terms of the patients' current age and their age in the first transfusion (P = 0.31, P = 0.89, respectively). Also, no statistical difference was observed between the two groups in terms of gender (P = 0.28). The frequency of blood transfusion per year did not differ between the two groups either (P 0.67). Eighteen patients =(17.1%)underwent splenectomy. There was no statistically significant relationship alloimmunization between and splenectomy (P = 0.37). Table II shows the frequency of main and minor blood groups in the patients with thalassemia major. The highest and lowest frequencies belong to O and AB groups (40.84% and 4.76%, respectively). Blood group A was seen in 33.3 % of the patients. Also, 85.5% of the patients were Rh-positive. Among the minor blood groups, D and KidD were the most and the least frequent (82.1% and 1.0%, respectively). According to the Table III, the patients in the positive alloantibody group had higher frequencies of Rh- and C- than those the negative alloantibody group (P = 0.03 and P = 0.05, respectively). As for the main blood groups, cc and E did not differ between the positive and negative alloantibody groups Table > 0.05). IV shows (\mathbf{P}) the relationship between alloantibody and the different blood groups of patients. As it can be seen, the positive and negative alloantibody groups had no significant difference in the frequency of sub-blood groups (P > 0.05). Based on Table V, there was a significant relationship between Rh and alloantibody (P = 0.03), while age, transfusion gender, start time, splenectomy, and number of transfusions had no significant relationship with alloantibody (P > 0.05).

Table I: The comparison of the patients in positive and negative alloantibody groups in terms of baseline characteristics (n = 105)

Variable		Alloc	Alloantibody		
		Positive $(n = 26)$	Negative (n =79)		
Age: mean (SD)(Year)		23.4 ± 10.6	20.9 ± 11.0	0.31	
Age of diagnosis: mean (SD)(Year)		17.2 ± 4.5	15.8 ± 3.6	0.2262	
Age in first transfusion (Year): mean (SD)		5 ± 1.4	4.9 ± 1.3	0.89	
Gender: n (%)	Female	15 (57.7)	36 (45.6)	0.28	
	Male	11 (42.3)	43 (54.4)		
Transfusion frequency in year: n (%)	≤12	20 (76.9)	63 (80.8)	0.67	
	> 12	6 (23.1)	15 (19.2)		
Splenectomy: n (%)	Positive	3 (11.5)	15 (19.2)	0.37	
	Negative	23 (88.5)	63 (80.8)		
Independent t-tests were used for the quantitative comparison of the two groups.					

Iran J Ped Hematol Oncol. 2023, Vol 13, No 4, 260-268

Keikhaei et al

Table II: Frequency	of the main a	and minor blood	groups in patients	with thalassemia major
rubic II. I requercy	<i>oj inc mani</i> c	and minor brood	Stoups in patterns	will indiassentia major

Main blood types	N (%)	
Α	35 (33.3)	
В	22 (20.9)	
AB	5 (4.76)	
0	43 (40.84)	
RH (Positive)	90 (85.5)	
Additional blood types	N (%)	
C (Positive)	86 (81.7)	
cc (Positive)	86 (81.7)	
D (Positive)	87 (82.1)	
E (Positive)	39 (36.8)	
ee (Positive)	69 (65.1)	
Kell (Positive)	5 (4.7)	
Fya (Positive)	82 (77.4)	
Fyb (Positive)	82 (77.4)	
jka (Positive)	82 (77.4)	
Jkb (Positive)	67 (63.2)	
duffy (posittive)	3 (2.8)	
Kidd (Positive)	1 (1.0)	
The variables are presented in frequencies and percentages.		

Table III: Comparison of the blood groups in terms of alloantibody production

Variable	Alloantibody		P-value	
	Positive $(n = 26)$	Negative $(n = 79)$		
Main blood groups: n (%)				
Α	9 (34.6)	26 (32.9)	0.22	
В	2 (7.7)	20 (25.3)		
AB	1 (3.9)	4 (5.1)	_	
0	14 (53.8)	29 (36.7)		
RH (Positive)	19 (73.1)	71 (89.9)	0.03*	
C (Positive)	18 (69.2)	68 (86.1)	0.05*	
cc (Positive)	22 (84.6)	65 (82.3)	0.78	
E (Positive)	7 (26.9)	32 (40.5)	0.21	
The variables are presented in frequencies and percentages. Independent t-tests were used for the quantitative comparison of the two groups.				

quantitative comparison of th *: It is statistically significant.

Iran J Ped Hematol Oncol. 2023, Vol 13, No 4, 260-268

Variable	Alloa	P-value	
-	<i>Positive</i> $(n = 26)$	Negative $(n = 79)$	-
D(n = 103)			0.10
positive	19 (73.1)	67 (87.0)	
negative	7 (26.9)	10 (13.0)	
ee(n = 88)			0.24
positive	15 (68.2)	53 (80.3)	
negative	7 (31.8)	13 (19.7)	
Kell $(n = 104)$			0.79
positive	1 (3.8)	4 (5.1)	
negative	25 (96.2)	74 (94.9)	
Fya (n = 101)			0.26
positive	22 (88.0)	59 (77.6)	
negative	3 (12.0)	17 (22.4)	
Fyb $(n = 100)$			0.88
positive	20 (80.0)	61 (81.3)	
negative	50 (20.0)	14 (18.7)	
Ika (n = 96)			0.18
positive	19 (76.0)	62 (87.3)	
negative	6 (24.0)	9 (12.7)	
Jkb (n = 101)			0.90
positive	17 (65.4)	50 (66.7)	
negative	9 (34.6)	25 (33.3)	
$Duffy \ (n=50)$			0.76
positive	1 (7.7)	2 (5.4)	
negative	12 (92.3)	35 (94.6)	
Kidd $(n = 42)$			0.07
positive	1 (10.0)	0 (0.0)	
negative	9 (90.0)	32 (100.0)	

Table IV: Compa	rison of the bloo	d groups in terms	s of alloantibody production
······································	, , , , , , , , , , , , , , , , , , ,	. o . r	· · · · · · · · · · · · · · · · · · ·

Table V: The association of alloantibody with several variables

Variable	P-value		
Age	0.31		
Gender	0.28		
Age at the start of the first transfusion	0.776		
Splenectomy	0.37		
Transfusion frequency	0.67		
Blood unit frequency	0.57		
Main blood groups	0.22		
Rh group	0.03*		
*: It is statistically significant. Chi-square test or Fisher's extract tests were			
used to test the association.			

264

Iran J Ped Hematol Oncol. 2023, Vol 13, No 4, 260-268

Discussion

The aim of the present study was to determine the frequency of major and subgroup antigens and their phenotypes in thalassemia major patients. Based on the findings, of 105 patients participating in this study, 26 (24.7%) had detectable alloantibodies in their serum. had a significant difference between the two groups of patients with positive and negative alloantibodies were significantly different in terms of Rh and C blood 0.05). Moreover, groups (P < no remarkable association was found between the existence of alloantibody and age, gender, spleen conditions and the time of first transfusion (P > 0.05). Thalassemia among the high-risk patients are individuals in the society in terms of the formation of alloantibodies. Red blood cell surface antigens are numerous, but, for blood transfusion, ABO and Rh groups are controlled. Since thalassemia patients constantly undergo blood transfusion, they may develop antibodies against other red blood cell antigens. This can cause blood reactions in the next transfusions. Among blood group antigens with subgroups D, E, e, C and c, Rh and Kell groups have more antigenic properties and are, therefore, able to stimulate the immune system (17). In a study by Koochakzadeh et al. (16), the prevalence of anti-red cell alloantibodies was 24.7%, which is the same as the findings of the present study (24.7%). This rate is much higher than the alloimmunization prevalence in thalassemia cases in Malaysia (8.6%)(18) and Pakistan (6.8%) (19). However, it is not comparable to the prevalence of alloimmunization among the known highrisk population in Taiwan (37%)(20). This disparity suggests that something other than geographical environment is involved in the high rate of alloimmunization.

Bhatti et al. (3) observed alloantibodies against red blood cells in 97.4% of their

patients, and most of these antibodies were related to Rh system antigens as well as anti-Kell, anti-JSb and anti-Jka types. In a similar study, Norol et al. (21) showed the prevalence of alloantibodies in 8.2% of thalassemia patients. The antibodies were generally against Jka and Jkb, Fya and S groups, and two types of antibodies were observed in one patient. Also, in a study in Greece, Spanos et al. (22) reported the highest amount of alloantibody were of anti-D and anti-Kell types.

In the present study, 24.7% of the patients had alloantibodies the highest amount of which was anti-E (6.6%), anti-Kell (5.7%) and anti-D (3.8%). This is in line with the results gained by Spanos et al. (22).

Consistent with our findings. Koochakzadeh et al. (16) found that age, gender, and blood type had no significant association with alloantibody positivity. Some previous studies, however, indicated an increase in the rate of alloantibodies with age through repeated blood transfusions. It should be noted that the role of age is of significance more at the first blood transfusion session.

Based on the results, the ABO blood type had no considerable effect on the increase of alloantibodies, which is in agreement with the results of a study by Eghbali et al. (23) conducted on an Iranian population. It seems that the main blood groups have no significant role in the generation of alloantibodies.

According to the results of this research and compared to other centers in the world, there are similarities among all the studies regarding the production of antibodies and the occurrence of blood reactions in patients who receive blood repeatedly.

In the current study, 17.9% of the participants had undergone splenectomy, but splenectomy did not make a statistically significant difference in alloantibody classes detected in the tests (P

Iran J Ped Hematol Oncol. 2023, Vol 13, No 4, 260-268

= 0.369), which is consistent with the study of Tahannejad et al. (24).

It seems that the role of the spleen in the phenomenon of alloimmunization is a dual and contradictory one. A group of researchers believe that splenectomy increases the production of alloantibodies in the serum because the center for collecting and removing foreign antigens is removed and the immune complexes are no longer cleaned (25, 26).

On the contrary, another team of researchers (27)not only failed to find such an association between the state of the spleen and the increase of alloantibody but even argued that splenectomy is not harmful because red blood cells are no longer removed from the bloodstream, and it reduces the need for transfusion. It is even suggested that splenectomy is a solution at the very beginning of blood collection (28).

Based on the findings, the age in the first transfusion had no statistically significant relationship with detection the of alloantibodies (P = 0.776). In this regard, Tahannejad et al. (24) reported no notable association between the time of the first transfusion and the occurrence of alloantibodies, which is in line with the present study. In contrast, as Hiradfar et al. (25) showed, alloimmunization had a remarkable relationships with the age at the beginning of transfusion, which is not consistent with the findings of this study.

The other factors involved in the production and spread of alloantibodies include the age of patients at the time of blood collection, the time interval between blood collections, and the number of transfusions. At the first glance, it may seem that aging and the number of transfusions induce an increase in the production of alloantibodies due to the increase in the amount of antigens entering the blood and sufficient time for immune stimulation and secondary responses. However, there is no evidence for this

direct relationship (26), although such a relationship has been reported in some studies (18, 29).

To justify the contradictory behavior in the discussion, some above researchers mention the phenomenon of tolerance as a mechanism that reduces the prevalence of alloantibody. Thus, if foreign antigens enter the body at the very beginning of infancy and when the child's immune responses have not yet developed, the immune system develops tolerance instead of responding to antigens; even in future encounters, it does not trigger a serious immune response. As another important point, the difference in the prevalence of alloantibody can be due to the nonstandardization some antibody of screening methods and the poor techniques of alloantibody identification and interpretation. One of the limitations of this study was the small sample size. Multicenter studies with bigger sample sizes suggest formulating evidence-based transfusion guidelines for thalassemia patients in Iran.

Conclusion

Considering the incidence of alloimmunization in thalassemia patients, most cases of which occur in Rh subgroups especially E, D and Kell groups, and based on a newly diagnosed case in a thalassemia patient, it is recommended to evaluate not only ABO and Rh groups but Kell, Kidd and Duffy groups as well. Determining the complete phenotype of the red cells in betathalassemia patients who are candidates for long-term treatment with blood before starting the treatment and performing screening tests for antibody(s) before each blood draw is currently the most practical way to prevent or reduce the formation of alloantibodies in patients with beta thalassemia major.

Conflict of interests

There is no conflict of interests.

266

Iran J Ped Hematol Oncol. 2023, Vol 13, No 4, 260-268

Funding

This research was supported by a grant from the Ahvaz Jundishapur University of Medical Sciences (Grant no: Th-9905). This article is based on Roya Khazai's dissertation for pediatric specialty from AJUMS.

References

1. Abdulqader AMR, Mohammed AI, Mohammed NI. Red Cell Alloimmunization and Autoimmunization in Multi-Transfused Thalassemia Patients in Sulaymaniyah Province-Iraq. Korean J Clin Lab Sci 2020;52(2):98-104.

2. Davari K, Soltanpour MS. Study of alloimmunization and autoimmunization in Iranian β -thalassemia major patients. Asian J. Transfus. Sci 2016;10(1):88-93.

3. Bhatti FA, Salamat N, Nadeem A, Shabbir N. Red cell immunization in beta thalassaemia major. **JCPSP** 2004;14(11):657-660.

4 Thedsawad Taka О. A. Wanachiwanawin W. Prevalence and of clinical significances red cell alloimmunization and red cell bound immunoglobulin in polytransfused G patients with thalassemias. Hematol 2019;24(1):208-214.

5. Amin M, Gholamhossein T, Majid N, Marziyeh H, Narges S, Akbar D. Prevalence of alloimmunization against RBC antigens in thalassemia major patients in South East of Iran. J Blood Disorders Transf 2013;4(147):2-9.

6. Keikhaei B, Far AH, Abolghasemi H, Mousakhani H, Ghanavat M, Moghadam M, et al. Red blood cell alloimmunization in patients with thalassemia major and intermediate in southwest Iran. IJBC 2013;6(1):41-46.

7. Abdulqader A, Mohammed A, Mohammed N. Red Cell Alloimmunization and Autoimmunization in Multi-Transfused Thalassemia Patients in Sulaymaniyah Province-Iraq. Korean J Clin Lab Sci2020;52:98-104.

8. Schonewille H, Van De Watering LM, Loomans DS, Brand A. Red blood cell alloantibodies after transfusion: factors influencing incidence and specificity. Transfusion med, 2006;46(2):250-256.

9. Chao Y-H, Wu K-H, Lu J-J, Shih M-C, Peng C-T, Chang C-W. Red blood cell alloimmunisation among Chinese patients with β-thalassaemia major in Taiwan. Blood Transfus 2013;11(1):71-79. Azarkeivan A. Ansari S. Ahmadi 10. MH. Hajibeigy B, Maghsudlu Nasizadeh S, et al. Blood transfusion and alloimmunization in patients with multicenter thalassemia: study. Pediatr. Hematol. Oncol,2011;28(6):479-485.

11. Sadeghian MH, Keramati MR, Badiei Z, Ravarian M, Ayatollahi H, Rafatpanah H, et alAlloimmunization among transfusion-dependent thalassemia patients. Asian J. Transfus. Sci, 2009;3(2):95-100.

12. Vaziri M, JavadzadehShahshahani H, Moghaddam M, Taghvaee N. Prevalence and specificities of red cell alloantibodies in transfusion-dependent beta thalassemia patients in Yazd. Iran. J. Pediatr. Hematol. Oncol 2015;5(2):93-99.

13. Davoudi-Kiakalayeh A, Mohammadi R, Pourfathollah AA, Siery Z, Davoudi-Kiakalayeh S. Alloimmunization in thalassemia patients: New insight for healthcare. Int. J. Prev. Med 2017;8 (2):11-18.

14. Hosseini MS, Jafari L, Heris RS, Gharehbaghian A. Red blood cell alloimmunization in Iran: A Comprehensive review of the literature. Asian J. Transfus. Sci 2020;14(1):4-11.

15. Davoudi-kiakalayeh A, Faranoush M, Haghbin A, Behboudi F. Reviewing the blood ordering schedule in a tertiary

Iran J Ped Hematol Oncol. 2023, Vol 13, No 4, 260-268

trauma center. Iran. J. Blood Cancer 2013;6(1):27-31.

16. Koochakzadeh L, Kajiyazdi M, Khoshhal F, Hashemi A, Khabazkhoob M. Prevalence of Alloantibodies in Thalassemia Patients and Its Relationship With Age, Gender and Blood Group. Acta Med Iran 2023: 1 (1):10-17.

17. Azarkeivan A, Ahmadi MH, Gharehbaghian A, Zolfaghari S, Nasizadeh S, Maghsudlu M, et al. Antibody screening and identification by gel method in thalassemic patients. Sci J Iran Blood Transfus Organ 2008;5(2):99-108.

18. Haslina MN, Ariffin N, Hayati II, Rosline H. Red cell immunization in multiply transfused Malay thalassemic patients. Southeast Asian J Trop Med Public Health 2006;37(5):10-15.

19. Bilwani F, Nabi G, Adil S, Usman M, Hassan F, Khurshid M. Frequency of irregular red cell alloantibodies in patients with thalassemia major: a bicenter study. JPMA 2005;55(12):563-569.

20. Wang LY, Liang DC, Liu HC, Chang FC, Wang CL, Chan YS, et al. Alloimmunization among patients with transfusion-dependent thalassemia in Taiwan. Transfusion Med 2006;16(3):200-203.

21. Norol F, Nadjahi J, Bachir D, Desaint C, Beaujean F, Bierling P, et al. Transfusion and alloimmunization in sickle cell anemia patients. SFTS 1994;1(1):27-34.

22. Spanos T, Karageorga M, Ladis V, Peristeri J, Hatziliami A, Kattamis C. Red cell alloantibodies in patients with thalassemia. Vox sang 1990;58(1):50-55.

23. Eghbali A, Rahimi-Afzal R, Mehrabi S, Sanatkar SA, Mousavi-Hasanzadeh M. Frequency and risk factors of red blood cell alloimmunization in thalassemia major patients in Markazi province. Iran. J. Pediatr. Hematol. Oncol 2019: 2 (2):50-55.

24. Tahannejad-Asadi Z, Elahi A, Mohseni A, Talebi M, Khosravi M, Jalalifar MA. Screening and identifying of erythrocyte alloantibodies in patients with Thalassemia major referred to Ahvaz Shafa hospital. Feyz Med Sci J 2013;17(2):165-172.

Hiradfar A, Keikhai B, Pedram M. 25. Determination of clinical prevalence and pattern predominant of **RBCs** alloimmunization transfusion among dependent thalassemic patients in Ahvaz. Jundishapur. J. Health. Sci 2010;9(5):8-14. Ahmed AM, Hasan NS, Ragab SH, 26. Habib SA, Emara NA, Aly AA. Red cell alloimmunization and autoantibodies in transfusion-dependent Egyptian thalassaemia patients. AMS 2010;6(4):592-598.

27. Gupta R, Singh DK, Singh B, Rusia U. Alloimmunization to red cells in thalassemics: emerging problem and future strategies. Transfus. Apher 2011;45(2):167-172.

28. Rahgozar S, Moafi A, Yavari F, Hourfar H. Alloantibody detection in major Beta Thalassemic patients transfused within less-than-20-day intervals. Sci. J. Iran 2005;1(2):1-9.

29. El Danasoury AS, Eissa DG, Abdo RM, Elalfy MS. Red blood cell alloimmunization in transfusion-dependent Egyptian patients with thalassemia in a limited donor exposure program. Transfusion 2012;52(1):43-47.

Iran J Ped Hematol Oncol. 2023, Vol 13, No 4, 260-268

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

DOI: 10.18502/ijpho.v13i4.13772